Travere Therapeutics/ US89422G1076 /
| 2024-05-03 9:59:49 PM | Chg. +0.11 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 6.26USD | +1.79% | 22,366 Turnover: 140,380.18 |
-Bid Size: - | -Ask Size: - | 6.45 | 6.21 |
GlobeNewswire
04-30
EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Tr...
GlobeNewswire
04-24
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for ...
GlobeNewswire
04-04
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genet...
GlobeNewswire
04-03
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Cong...
GlobeNewswire
03-18
American Kidney Fund Convenes Nation’s Kidney Community for 2024 Kidney Action Week™ March 18-22
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-13
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-11
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administrat...
GlobeNewswire
02-23
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
02-15
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire
02-08
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
02-01
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
GlobeNewswire
01-25
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize ...
GlobeNewswire
01-02
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-12-29
Visionary Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its ...
GlobeNewswire
2023-12-14
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of ...
GlobeNewswire
2023-12-05
American Kidney Fund Hosts Fourth National Summit on Unknown Causes of Kidney Disease
GlobeNewswire
2023-12-04
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for b...
GlobeNewswire
2023-11-30
American Kidney Fund Renews Calls for Early Diagnosis and Treatment of Chronic Kidney Disease in Ne...
GlobeNewswire
2023-11-21
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
